Towards a systematic assessment of assay interference: Identification of extensively tested compounds with high assay promiscuity

A large-scale statistical analysis of hit rates of extensively assayed compounds is presented to provide a basis for a further assessment of assay interference potential and multi-target activities. A special feature of this investigation has been the inclusion of compound series information in activity analysis and the characterization of analog series using different parameters derived from assay statistics. No prior knowledge of compounds or targets was taken into consideration in the data-driven study of analog series. It was anticipated that taking large volumes of activity data, assay frequency, and assay overlap information into account would lead to statistically sound and chemically meaningful results. More than 6000 unique series of analogs with high hit rates were identified, more than 5000 of which did not contain known interference candidates, hence providing ample opportunities for follow-up analyses from a medicinal chemistry perspective.

[1]  Jürgen Bajorath,et al.  How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds. , 2017, Journal of medicinal chemistry.

[2]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[3]  Jonathan Bisson,et al.  Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery? , 2015, Journal of medicinal chemistry.

[4]  Christopher P Austin,et al.  Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.

[5]  Michael J. Keiser,et al.  Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors† , 2010, Journal of medicinal chemistry.

[6]  Daniel J. Warner,et al.  Matched molecular pairs as a medicinal chemistry tool. , 2011, Journal of medicinal chemistry.

[7]  Jürgen Bajorath,et al.  Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology. , 2016, Journal of medicinal chemistry.

[8]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[9]  B. Shoichet.  Screening in a spirit haunted world. , 2006, Drug discovery today.

[10]  J. Baell,et al.  Chemistry: Chemical con artists foil drug discovery , 2014, Nature.

[11]  Jürgen Bajorath,et al.  Activity profiles of analog series containing pan assay interference compounds , 2017 .

[12]  Jürgen Bajorath,et al.  Determining the Degree of Promiscuity of Extensively Assayed Compounds , 2016, PloS one.

[13]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[14]  Kenneth M Merz,et al.  The Ecstasy and Agony of Assay Interference Compounds. , 2017, ACS chemical neuroscience.

[15]  Thorsten Meinl,et al.  KNIME: The Konstanz Information Miner , 2007, GfKl.

[16]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[17]  Alexander Tropsha,et al.  Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS , 2017, J. Chem. Inf. Model..

[18]  J. Bajorath,et al.  Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.

[19]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[20]  J. Bajorath,et al.  Local structural changes, global data views: graphical substructure-activity relationship trailing. , 2011, Journal of medicinal chemistry.

[21]  R. Iyengar,et al.  Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.

[22]  J. Irwin,et al.  An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.

[23]  Jayme L. Dahlin,et al.  Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR. , 2015, Bioorganic & medicinal chemistry letters.

[24]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[25]  Jameed Hussain,et al.  Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets , 2010, J. Chem. Inf. Model..

[26]  A. C. Krueger,et al.  Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives. , 2012, Bioorganic & Medicinal Chemistry Letters.

[27]  Jürgen Bajorath,et al.  MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs , 2012, J. Chem. Inf. Model..

[28]  Jürgen Bajorath,et al.  Entering the ‘big data’ era in medicinal chemistry: molecular promiscuity analysis revisited , 2017, Future science OA.

[29]  Jayme L. Dahlin,et al.  The Essential Medicinal Chemistry of Curcumin , 2017, Journal of medicinal chemistry.

[30]  Jayme L. Dahlin,et al.  PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS , 2015, Journal of medicinal chemistry.

[31]  A. Linden,et al.  A simple approach for the regioselective synthesis of imidazo[1,2 -a ]pyrimidiones and pyrimido[1,2 -a]pyrimidinones , 2006 .

[32]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[33]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[34]  Jürgen Bajorath,et al.  Matched molecular pairs derived by retrosynthetic fragmentation , 2014 .

[35]  Jonathan B Baell,et al.  Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS). , 2016, Journal of natural products.